Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of erdafitinib versus vinflunine, docetaxel, or pembrolizumab in advanced urothelial carcinoma with selected FGFR alterations
MOH_2018-05-21_002346Phase 3Not yet recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- May 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of erdafitinib in transitional cell carcinoma (TCC) and bladder cancer (4 arms), sponsored by Janssen Pharmaceutical. Planned start May 2018; status: not yet recruiting.
02
Drugs
erdafitinib
03
Conditions
transitional cell carcinoma (TCC)bladder cancer
Beyond the preview
Go deeper on MOH_2018-05-21_002346.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2018-05-21_002346.